Lots of opportunities yet to comeNo matter how dissapointing the last quarter was for microbix they still did relatively well overall. The pandemic has created opportunities and challenges at the same time. The tech stocks are overvalued and biomedicals are undervalued. Lots of opportunities yet to come for Microbix. Just need supply chains and suppliers to adjust to the new challenges that the pandemic has brought to the health system. Once that happens things will be much better. Microbix is positioned to handle this storm relatively well